In Vitro Diagnostics Industry Overview

The global in vitro diagnostics market size is expected to reach USD 118.72 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 6.75% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers diagnostics for users.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics Market

These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global ovarian cancer diagnostics market size was valued at USD 4.60 billion in 2023 and is expected to grow at a CAGR of 5.0% from 2024 to 2030. 
  
  
• The global multi cancer early detection market size was estimated at USD 1.12 billion in 2024 and is projected to grow at a CAGR of 17% from 2025 to 2030. 

In Vitro Diagnostics Market Segmentation

Grand View Research has segmented the global in vitro diagnostics market report based on product, technology, application, end-use, test location, and region:

In Vitro Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments
• Reagents
• Services

In Vitro Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassay
  • Instruments
  • Reagents
  • Services
• Hematology
  • Instruments
  • Reagents
  • Services
• Clinical Chemistry
  • Instruments
  • Reagents
  • Services
• Molecular Diagnostics
  • Instruments
  • Reagents
  • Services
• Coagulation
  • Instruments
  • Reagents
  • Services
• Microbiology
  • Instruments
  • Reagents
  • Services
• Others
  • Instruments
  • Reagents
  • Services

In Vitro Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Diseases
• Drug Testing
• Others applications

In Vitro Diagnostics Test Location Outlook (Revenue, USD Million, 2018 - 2030)

• Point of Care
• Home-care
• Others

In Vitro Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals
• Laboratory
• Home-care
• Others

In Vitro Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
  • Singapore
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Companies profiled:

• Abbott
• bioMérieux SA
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Qiagen
• Sysmex Corporation
• Charles River Laboratories
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.
• Danaher Corporation
• BD
• Hoffmann-La Roche Ltd.

Recent Developments

• In January 2024, Cepheid's Xpert Xpress MVP received FDA clearance and CLIA waiver, offering rapid multiplex PCR testing for Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomoniasis (TV), improving targeted treatment and patient outcomes in near-patient settings.
• In December 2023, ARUP Laboratories and Medicover collaborated to provide diagnostic and healthcare services in Europe. ARUP Laboratories has developed AAV5 DetectCDx in collaboration with BioMarin Pharmaceutical Inc. to select therapies for severe hemophilia A patients.
• In November 2023, Veracyte joined Illumina aimed to develop molecular tests for decentralized IVD applications. Companies are focusing on the development of Prosigna breast cancer and Percepta nasal swab tests of Veracyte.
• In October 2023, Promega Corporation announced its plan to develop and commercialize companion diagnostics kits with GSK plc to identify cancer patients with MSI-H solid tumors.
• In February 2023, Unilabs announced investing over USD 200 million in Siemens Healthineers' technology and acquiring more than 400 laboratory analyzers to strengthen its laboratory infrastructure.
• In February 2023, F. Hoffmann-La Roche Ltd. collaborated with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies. Companion diagnostic technologies include digital pathology, NGS, PCR, immunoassays, and immunohistochemistry.

Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.